Group 1 - The core viewpoint is that Chinese pharmaceutical companies account for approximately 30% of the global BD transaction total, indicating their growing importance in the global pharmaceutical landscape [1] - The trend shows a shift from domestic pharmaceutical companies being demand-side players in innovative drug projects to becoming providers, with BD income emerging as a significant revenue source [1] - The small nucleic acid drug market is viewed positively, with strong catalysts in commercialization, clinical development, and BD transactions [1] Group 2 - The Guotai ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies [1] - The performance from September 24, 2024, to October 31, 2025, shows that the Sci-Tech Innovation Drug Index and the Hang Seng Hong Kong Stock Connect Innovation Drug Index increased by 143.70% and 135.34% respectively during the market rebound [1] - The Sci-Tech Innovation Drug Index may help capture the elasticity of the Sci-Tech Innovation Board when market risk appetite improves [1]
20cm速递丨关注科创创新药ETF国泰（589720）投资机会，国内创新药研发呈现“多快好省”优势
Mei Ri Jing Ji Xin Wen·2025-11-27 07:32